Form 8-K PLIANT THERAPEUTICS, For: Jul 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RBC Capital on Pliant Therapeutics (PLRX): 'we believe there was nothing concerning emerging from the call '
July 11, 2022 10:22 AM EDTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $54.00 price target on Pliant Therapeutics (NASDAQ: PLRX)
The analyst comments "We highlight several tidbits emerging from the company's conference call this morning with more details from the ph.II '809 IPF study. In... More
Pliant Therapeutics Inc. (PLRX) Halted Again on Volatility, Up 141%
July 11, 2022 9:47 AM EDTPliant Therapeutics Inc. (NASDAQ: PLRX) Halted Again on Volatility, Up 141%
Pliant Therapeutics Inc. (PLRX) Halted on Volatility, Up 103%
July 11, 2022 9:32 AM EDTPliant Therapeutics Inc. (NASDAQ: PLRX) Halted on Volatility, Up 103%
Pliant Therapeutics (PLRX) Shares Surge, H.C. Wainwright Comments on PLN-74809, Keeps $45 PT
July 11, 2022 9:01 AM EDTH.C. Wainwright analyst Ed Arce reiterated a Buy rating and $45.00 price target on Pliant Therapeutics (NASDAQ: PLRX).
The analyst comments "Last night, we spoke with Pliant management following yesterday's eagerly awaited release of the top-line results of its Phase 2a INTEGRIS-IPF study (NCT04396756) of lead drug PLN-74809 administered over 12 weeks in 90 patients with idiopathic pulmonary fibrosis (IPF). Importantly, across the three active dose arms (40, 80 and 160 mg) plus placebo, 80% of enrolled patients were on stable doses of standard-of-care (SoC), equally distributed between nintedanib and pirfenidone. As we expected, and consistent with prior... More
Pliant Therapeutics Inc. (PLRX) Climbs 15% Following Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809
July 11, 2022 7:07 AM EDTPliant Therapeutics Inc. (NASDAQ: PLRX) Climbs 15% Following Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809
... More